Discover the 5 best Streamlight rechargeable flashlights for 2025. From the EDC Wedge SL to the 2,000-lumen ProTac 2.0, find ...

A 3D virtual model of the PKMYT1–PROTAC–CRBN ternary complex depicting how Insilico Medicine’s bifunctional proteolysis-targeting chimera (PROTAC) D16-M1P2 (shown in yellow) inhibits ...

Reducing the time and expense of engineering PROTAC degraders remains a significant challenge in the pharmaceutical industry. A PROTAC is composed of an E3 ligase ligand (E3-L), a protein of interest ...

Having already stripped back their development plans for the estrogen receptor (ER) degrader vepdegestrant on the back of mixed data, Pfizer and Arvinas have now decided to wash their hands of the ...

As an added bonus, ProTac can be set to a "flicker mode" in which the PDLC continuously (and rapidly) switches back and forth between its transparent and opaque states. This allows the system to ...

The study, published in IEEE Transactions on Robotics, is claimed to present a scalable approach to multimodal robotic perception. At the core of ProTac is a polymer-dispersed liquid crystal (PDLC) ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Arvinas may soon be looking for a new partner for a ...

We may receive a commission on purchases made from links. It shouldn't come as a surprise that Harbor Freight carries a number of good flashlights under different brand names, filling a variety of ...

In this phase 3, open-label, randomized trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer who had received one previous line ...

Power can go out at any time of the year. A battery-powered flashlight or lantern is a must have. FOX 26 Meteorologist John Dawson shows us a powerful light that is rechargeable and waterproof. STILLS ...

Pfizer and Arvinas’ estrogen receptor (ER) degrader has failed a key part of its first phase 3 test, although the companies have pointed to success in a subpopulation to suggest the therapy still has ...